⚑ FOUNDING COHORT CLOSING SOON Only 8 of 20 founding spots remain. Applications reviewed within 48 hours.
Invitation-Only · Founding Cohort · Now Forming

Your research doesn't end
at publication.

FHIN is building the most rigorous clinical intelligence network in biopharma. We're inviting fewer than 20 researchers to help found it — and to have their work seen, cited, and recognized far beyond the journal page.

See If You Qualify
8 spots remaining
Oncology · AMC RWE · R1 Genomics · R1 FHIN Core Rare Disease CRO · Phase II Biomarkers · EU CNS · R1 Metabolic · Biotech

You've run the study.
Written the paper.
Then what?

The data — the part that took years and millions to generate — gets buried in a supplementary file that a handful of people will ever open. The insights that could inform the next ten drug programs sit in a folder that no search engine indexes, no intelligence platform ingests, and no other researcher can build on.

"We already know our data is worth more than a PDF appendix. We just haven't had a home that treats it that way."
60%+
of clinical trial datasets are never reused after publication — even when the findings are highly cited. Source: Navar et al., NEJM (2016); CSDR analysis of trial data sharing requests
3–7 yrs
Average time from data generation to meaningful reuse — when it happens at all. FHIN is designed to collapse that gap. Source: Institute of Medicine, "Sharing Clinical Trial Data" (2015)
$0
Revenue or recognition most researchers receive when their archived data is used to inform a $1B drug development decision. Based on current academic data-sharing incentive structures

It's not that the data isn't valuable.
It's that the infrastructure to surface that value didn't exist.

Until now. FHIN is not a repository. It is not another archive. It is a live, quality-scored intelligence network — where your contribution is indexed, credited, and seen by the biopharma teams who need it most.

This isn't a database upload form.
It's an invitation.

Founding Contributors are not users. They are co-architects of the most rigorous clinical dataset network being built in biopharma. That status carries real, permanent benefits.

Permanent Founding Contributor Badge

Displayed on your public FHIN profile forever. Your institution and dataset domain are indexed and credited — not anonymized.

Citable Dataset Profile

Every contributed dataset gets a unique FHIN identifier, a quality score, and a public profile — giving your data a citation lifecycle beyond the original paper.

90 Days of Full Platform Access

Unrestricted access to AimwellBio's full intelligence stack — Cortex briefings, competitive signals, and the complete FHIN dataset library — free for the founding cohort period.

Early API Access

As FHIN grows, the API will be the primary interface for intelligence teams. Founding Contributors have first access before general availability.

FHIN Credits (Recurring)

Quality contributions earn credits that can be redeemed for premium platform features — a direct, ongoing return on every dataset you submit.

How your work is recognized
as the network grows

Founding Contributors start at the top of the recognition stack — and their status never expires.

Entry
Observer
Read access · No contribution required
Active
Contributor
1+ dataset submitted · Credits eligible
Partner
Institutional
Multi-contributor org access
FHIN QUALITY SCORE Peer-reviewed · Last updated Apr 2026 94 /100 EXCEPTIONAL Completeness 92 Reproducibility 95 Clinical Relevance 93 Metadata Richness 96 ● FOUNDING CONTRIBUTOR

We don't accept everything.
That's the point.

Multi-Dimensional Quality Scoring

Every dataset is scored across completeness, reproducibility, clinical relevance, and metadata richness before it enters the network. A high score is an earned credential — not an automatic one.

Human + AI Review

Submissions go through an admin review workflow that combines automated quality checks with expert human review. Your name is attached to a standard that means something.

Federated by Design

FHIN is not a data warehouse. Contributors retain control of their underlying data. What you contribute is a curated, de-identified dataset — governed by your institution's standards.

Used by Biopharma Intelligence Teams

FHIN feeds directly into AimwellBio's Cortex AI engine — used by biopharma teams for competitive intelligence, indication selection, and pipeline analysis. Your data is not archived. It is actively used.

The founding cohort
is nearly full.

We made a deliberate decision to limit the founding cohort to 20 researchers. Not because of technical constraints — because the quality of the first contributors defines the standard for everyone who follows. We are not filling seats. We are selecting co-founders of a network.

12 spots filled. 8 remaining. Applications reviewed within 48 hours. When the cohort closes, Founding Contributor status ends permanently.

Academic researchers at R1 or AMC institutions
CRO or biotech data managers and scientists
Active or recently published clinical/translational work
At least one de-identified dataset available to contribute
Oncology, rare disease, CNS, metabolic, or immunology focus
Commitment to data quality over volume

Your work deserves
a network built for it.

Applications are reviewed personally. We respond within 48 hours. If you're accepted, you'll receive direct onboarding support and your Founding Contributor profile goes live immediately.

What happens after you apply:
1. We review your application and dataset area (48 hrs).
2. You receive a personalized confirmation and onboarding guide.
3. Your contributor profile goes live the moment your first dataset is reviewed.

R
S
M
+9

12 researchers have already joined the founding cohort

By applying, you agree that AimwellBio may follow up via the provided email. No data is shared with third parties. Applications are reviewed by a human — not a bot.

Application received.

You'll hear from us within 48 hours. We review every application personally. Thank you for your interest in FHIN — we'll be in touch.